Approval · Notice of Compliance 35672 · 2025
PAVBLU: Notice of Compliance 35672
Issued July 8, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35672
- Date
- July 8, 2025
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- ELYEA
Products in this notice
Medicinal ingredients
- AFLIBERCEPT 2 MG per 0.05ML
- AFLIBERCEPT 2 MG per SYR